Please assess the completion status of the following clinical trial:

Trial Title: Mirtazapine to Reduce Methamphetamine Use Among MSM With High-risk HIV Behaviors

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. HIV-negative by rapid test, or documentation of HIV infection with a laboratory result of a positive HIV test;~2. male gender;~3. reports having anal sex with men in the prior 3 months while using methamphetamine;~4. diagnosed with methamphetamine dependence as determined by SCID;~5. interested in stopping or reducing methamphetamine use;~6. at least one methamphetamine-positive urine at screening and run-in period;~7. no known allergies to mirtazapine;~8. no current acute illnesses requiring prolonged medical care;~9. no chronic illnesses that are likely to progress clinically during trial participation;~10. able and willing to provide informed consent and to be followed over a 3-month period;~11. age 18-60 years;~12. baseline CBC, total protein, albumin, glucose, alk phos, creatinine, BUN and electrolytes without clinically significant abnormalities as determined by investigator in conjunction with symptoms, physical exam, and medical history.~Exclusion Criteria:~1. evidence of current major depression, as determined by SCID;70~2. history of bipolar disorder or psychosis, as determined by SCID;~3. taking anti-depressant or other psychotropic medication within the last 30 days, including mirtazapine or a monoamine oxidase (MAO) inhibitor;~4. currently using or unwilling not to use pseudoephedrine-containing products for trial duration (causes false positive urines for methamphetamine use);~5. current CD4 count \< 200 cells/mm3;~6. measured moderate or severe liver disease (AST, ALT, and total bilirubin \> 3 times upper limit of normal) and/or any symptoms of current liver disease;~7. impaired renal function (creatinine clearance \< 60 ml/min);~8. currently participating in another research study;~9. any condition that, in the principal investigator's judgment, interferes with safe study participation or adherence to study procedures.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: t

Study Arms:
- Mirtazapine (Type: ACTIVE_COMPARATOR): mirtazapine 30 mg daily
- Placebo (Type: PLACEBO_COMPARATOR): placebo 30 mg daily

Based on this trial design, predict the completion outcome and termination type (if applicable).